Eleftherios Pelechas

1. Tsigaridas N, Troganis E, Pelechas E. Ischemic Colitis, Medical annals of northwestern Greece, 2011;7(2):50-57.

2. Pelechas E, Improvement of Gastroesophageal reflux in patients with obstructive sleep apnoea treated with continuous positive airway pressure, J Gastrointestin Liver Dis. 2012 Dec;21(4):443

3. Tsigaridas N, Pelechas E. Rash in association with fever – Clinical case of non-Hodgkin T-lymphoma, Medical annals of northwestern Greece, 2012;8(2):9-14.

4. Pelechas E, Gastroesophageal Reflux Disease: epidemiological data, symptomatology and risk factors, Revista Medico-chirurgicala a Societatii de Medici si Naturalisti din Iasi, Romania, 2013 Jan;117(1):183-188.

5. Pelechas E, A comparative study of job satisfaction between two regional hospitals in Greece, Archives of Hellenic Medicine, 2013 May;30(3):325-334.

6. Pelechas E, Impact of nasal Continuous Positive Airway Pressure on Heart Rhythm in patients with Obstructive Sleep Apnea/Hypopnea syndrome, Minerva Medica, 2014;105(3):255-60

7. Pelechas E, Hospitalized elderly patients due to infection and factors associated with mortality, Medical annals of northwestern Greece, 2014;10(1):66-71.

8. Tsigaridas N, Pelechas E, Insulin and heparin administration for the treat. of hypertriglyceraemic pancreatitis, Medical annals of northwestern Greece, 2014;10(1):37-42.

9. Pelechas E, Tylosis palmaris et plantaris familiaris in association with Dupuytren’s contracture – A case of ectodermal anomaly, Archives of Hellenic Medicine, 2015;32(1):106-110.

10. Tsigaridas N, Naka K, Tsapogas P, Pelechas E, Spinal cord stimulation in refractory angina A systematic review of randomized controlled trials, Acta Cardiologica, 2015;70(2):233-243

11. Pelechas E, Electrocardiographic Manifestations in Three Psychiatric Patients with Hypothermia – Case Report. Hellenic Journal of Cardiology 2016;1(2):1007-9

12. Pelechas E Scleroderma: a progressive insidious disease The Doctor 2016;22:81-82

13. Pelechas E Fibromyalgia and Sleep Disturbance: A Vicious Circle. Austin Arthritis. 2016; 1(3):1013.

14. Pelechas E, Transfusion-related acute lung injury in a patient with SLE. Clin Exp Rheumatol 2017 Jan 27

15. Kaltsonoudis E, Pelechas E, Dermatomyositis sine myositis – Case presentation. MJR 2017;28(1):67-8.

16. Pelechas E, Sirukumab: a promising therapy for RA. Expert Opin Biol Ther. 2017 Apr 4

17. Pelechas E. JAK inhibitors: a promising direction for treating RA. Int J Pharm Sci Dev Res 2017;3(1):29.

18. Archimandriti D, Iliou C, Tzallas AT, Pelechas E, Comparison of tuberculin skin test and interferon-gamma release assay screening in patients with RA starting anti-tumor necrosis factor therapy. ARD, 2017;76(suppl 2):1193

19. Tsirves G, Voulgari PV, Archimandriti D, Pelechas E, Inner ear involvement in Systemic Rheumatic Diseases. ARD, 2017;76(suppl 2):1217

20. Pelechas E, Henoch-Schonlein Purpura in an Adult 53 years old. Archives of Clinical and Medical Case Reports, 2017;1(1):1-3.

21. Pelechas E, A Case of Recalcitrant PsA to TNF Inhibitors Improved After Administration of Secukinumab, an IL-17A Inhibitor. Rheumatol Ther October 11 2017

22. Pelechas E, Hydroxychloroquine-induced dark butterfly rash in a RA patient. Rheumatology (Oxford) October 23 2017

23. Pelechas E, ABP 501 for the treat. of RA. Expert Opin Biol Ther. 2018 Jan 19. doi: 10.1080/14712598.2018.1430760

24. Pelechas E, An uncommon presentation of Granulomatosis with Polyangiitis. MJR 2018;29(1):38-40.

25. Kaltsonoudis E, Pelechas E, Unmet needs in the treat. of RA. An observational study and a real-life experience from a single university center. Semin Arthritis Rheum. In Press. Available online 22 June 2018

26. [Acknowledgement] Migkos MP, Epidemiological characteristics of PsA. Clin Exp Rheumatol 2018 Oct 8.

27. Pelechas E, GA development in a patient with RA treated with tocilizumab: case-based review. Rheum Int 2018

28. Pelechas E, Etanercept Biosimilar SB-4. Expert Opin Biol Ther 2019 Jan 8

29. Pelechas E, Unmet needs in the treat. of AS: a long-term observational study from a single university center. Rheum Int 2019

30. Pelechas E, Golimumab for RA. J Clin Med 2019;8(3):387

31. Kaltsonoudis E, Pelechas E, The impact of temporal artery biopsy for the diagnosis of GCA in clinical practice in a tertiary university hospital. PLoS One 2019;14(3):30210845

32. Drosos AA, Pelechas E, Cr of the hands and wrists in RA. What a rheumatologist should know and how to interpret the radiological findings. Rheum Int. 2019 May 22

33. Kaltsonoudis E, Pelechas E, Comment on: Assessments of the unmet need in the management of patients with RA: analyses from the NOR-DMARD registry. Rheumatology (Oxford) 2019 Jun 6

34. Tsirves GK, Voulgari PV, Pelechas E, Cochlear involvement in patients with systemic ARDs: a clinical and laboratory comparative study. Eur Arch Otorhinolaryngol 2019 May 30

35. Pelechas E, Chemotherapy-induced palmo-plantar erythrodysesthesia and leukonychia striata in a SLE patient. Fortune J Rheumatol 2019;1(1):007-008.

36. Pelechas E, Cs as a cause of Catastrophic RA. Fortune J Rheumatol 2019;1(1):015-017.

37. Kaltsonoudis E, Pelechas E, Maintained Clinical remission in AS patients switched from reference Infliximab to its biosimilar: An 18-month comparative open-label study. J Clin Med. 2019;8(7):956

38. Drosos AA, Pelechas E, RA Treat.. A Back to the Drawing Board Project or High Expectations for Low Unmet Needs? J Clin Med. 2019;8(8):pii:E1237

39. Kaltsonoudis E, Pelechas E, Reply to the Editor. Semin Arthritis Rheum. 2019 Aug 1. pii: S0049-0172(19)30477-9

40. Pelechas E, Clinical evaluation of the safety, efficacy and tolerability of sarilumab in the treat. of moderate to severe RA. Ther Clin Risk Manag. 2019;15:1073-1079

41. Pelechas E. Diagnosis and Management of SLE – educational quiz. Doctors.net.uk. 2020

42. Drosos AA, Pelechas E, Treat. strategies are more important than drugs in the management of RA. Clin Rheumatol (2020)

43. Pelechas E, Autologous hematopoietic stem cell transplantation in SSc patients. J Stem Cell Ther Transplan. 2020;4:001-002

44. Pelechas E, Adalimumab-induced myasthenia gravis: case-based review. Rheum Int

45. Drosos AA, Pelechas E, Radiological findings of the Cs in RA Patients: What a Rheumatologist Should Know. Curr Rheumatol Rep. 2020;22:19

46. Kaltsonoudis E, Pelechas E, Neuroinflammatory events after anti-TNFα therapy. ARD 20 May 2020

47. Pelechas E, Bertolotti syndrome: a not-to-miss cause of chronic low back pain in young adults. Acta Reumatol Port 2020;45(1):58-60

48. Pelechas E, RA: Treat. evolution over the years. Open J Pharmacol Pharmacother 2020;5(1):024-026

49. Venetsanopoulou AI, Pelechas E, The lipid paradox in RA: the dark horse of the augmented CV risk. Rheum Int 2020

50. Drosos AA, Pelechas E, Therapeutic Options and Cost-Effectiveness for RA Treat.. Curr Rheumatol Rep. 2020;22:44

51. Alamanos Y, Pelechas E, Incidence of spondyloarthritis and its subtypes: a systematic review. Clin Exp Rheumatol. 2020 Sep 4

52. Pelechas E, Anti-Rheumatic drugs for the fight against the novel coronavirus infection (SARS-CoV-2): What is the evidence? MJR. 2020;31(Suppl 2):259-67

53. Pelechas E, Biosimilars and retention rates in patients with AS. Clin Exp Rheumatol. 2020 Oct 18

54. Pelechas E, Recent advances in the opioid mu receptor based pharmacotherapy for RA. Expert Opin Pharmacother

55. Pelechas E, Preclinical discovery and development of adalimumab for the treat. of RA. Expert Opin Drug Discovery. 2020

56. Pelechas E, Occupational mimics of RA: hair dye-induced arthritis. Rheum Int. 2020

57. Pieta A, Pelechas E, Calcified constrictive pericarditis resulting in tamponade in a patient with SLE. Rheum Int. 2020

58. Pelechas E, Cutaneous autoimmune phenomena of the anti-TNFa biosimilars. Case-based review. Curr Rheumatol Rev. 2020 Nov 19

59. Georgiadis AN, Pelechas E, Correspondence on “CV effects of b versus csDMARD therapy in treat. naïve, early RA”. ARD. 2021 Feb 8

60. Pelechas E, Insulin resistance in patients with RA. Rheum Int. 2021;41(6):1185-1186

61. Migkos MP, Kaltsonoudis E, Pelechas E, Use of cs and biologic DMARDs in patients with rheumatic diseases contracting COVID-19: a single-center experience. Rheum Int 2021;41(5):903-909

62. Pelechas E, MTX and interstitial lung disease. Is there a real causative factor? Rheum Int 2021 May 27

63. Pelechas E, COVID-19 in patients with gout on colchicine. Rheum Int 2021;5:1-5.

64. Drosos AA, Pelechas E, Biologic Therapies and Autoimmune Phenomena. MJR. 2021;32(2):96-103

65. Drosos AA, Pelechas E, A not-to-miss cause of severe cs pain in a patient with RA: a case-based review. MJR 2021

66. Skalkou A, Pelechas E, TNF-induced Lupus. A Case-Based Review. Curr Rheumatol Rev. 2021 Nov 1

67. Tsamis KI, Boutsoras C, Kaltsonoudis E, Pelechas E, Clinical features and diagnostic tools in idiopathic inflammatory myopathies. Crit Rev Clin Lab Sci. November 2021

68. Drosos AA, Pelechas E, Seronegative Erosive Arthritis Following SARS-CoV-2 Infection. Rheumatol Ther November 2021

69. Drosos AA, Pelechas E, A not-to-miss cause of severe cs pain in a patient with RA: a case-based review. MJR. 2021;32(3):256-263

70. Drosos AA. Pelechas E, Colchicine against SARS-CoV-2 infection: What is the evidence? Rheumatol Ther. 2022 Feb 2:1-11

71. Drosos AA, Pelechas E, A patient with symmetrical polyarthritis. The value of cr for a correct diagnosis. Rheumatol Ther. 2022 Feb 3:1-11

72. Drosos AA, Pelechas E, Long COVID from rheumatology perspective: a simple mimicker or promoter of autoimmunity? Clin Rheumatol. 2022 Feb 11